IMMUNOGENE ZUSAMMENSETZUNG

European patent · EP2928489 · In force

Register entry

Publication number
EP2928489
Application number
EP13801540
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Dec 3, 2013
Published
Oct 14, 2015
Granted
Feb 27, 2019
Protection ends at the latest
Dec 2, 2033
Next annual fee due
Dec 31, 2026
IPC classes
A61K 39/08 (2006.01)
C07K 14/33 (2006.01)
Priority
GB 201221875 05.12.2012
PCT application
PCT/EP2013/075405 03.12.2013
PCT publication
WO2014/086787 12.06.2014
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jan 1, 2026

    Change

    Published in Swissreg on 01.01.2026

  2. Jan 1, 2025

    Change

    Published in Swissreg on 01.01.2025

  3. Jan 1, 2024

    Change

    Published in Swissreg on 01.01.2024

  4. Jan 1, 2023

    Change

    Published in Swissreg on 01.01.2023

  5. Mar 15, 2019

    Agent entered

    Representative
    Isler & Pedrazzini AG, Postfach 1772, 8027 Zürich

    Published in Swissreg on 15.03.2019

  6. Feb 27, 2019

    Granted

    Published in Swissreg on 27.02.2019

Parties

Holder

GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89, 1330 Rixensart, BE

Agent

Isler & Pedrazzini AG

Postfach 1772, 8027 Zürich

Inventor

WALLEMACQ, Hugues

1330 Rixensart, BE

BOUTRIAU, Dominique

1330 Rixensart, BE

GERMAIN, Sophie Marie Jeanne Valentine

1330 Rixensart, BE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.